Devroe Eric
SEC CIK 1950573 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | COO | 146.3K | $17.2K | $1,214 | 17 | 2022-11-14 | 2026-08-18 |
Most active insiders at ACRV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Blume-Jensen Peter | Pres, CEO, Dir | $82.3K | $34.4K |
| 2 | Devroe Eric | COO | $17.2K | $1,214 |
| 3 | Levy Adam D. | CFO | $15.0K | $1,793 |
| 4 | Miller Mary | CLO | — | $1,380 |
| 5 | Gamelin Erick | Chief Development Off | — | $804.00 |
| 6 | Peterson Katharine | CAO | — | $203.01 |
| 7 | Levin Michaela | Chief Business Off | — | — |
| 8 | Palani Santhosh | Dir | — | — |
| 9 | Masson Kristina | EVP - Business Ops, Dir | — | — |
| 10 | DiRocco Derek | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 16:07 | 2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | S - Sale | $2.01 | -604 | 146.3K | -0.4% | -$1,214 | |
| 2026-05-20 16:29 | 2026-05-18 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | A - Grant | $0.00 | +73.0K | 147.0K | +99% | $0 | |
| 2026-05-18 16:10 | 2026-05-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $1.92 | -613 | 74.0K | -0.8% | -$1,177 | |
| 2026-02-18 | 2026-02-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $1.63 | -723 | 74.6K | -1.0% | -$1,178 | |
| 2026-01-15 | 2026-01-13 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | P - Purchase | $1.72 | +10.0K | 75.3K | +15% | +$17.2K | |
| 2025-11-18 | 2025-11-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $2.24 | -613 | 65.3K | -0.9% | -$1,373 | |
| 2025-08-18 | 2025-08-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $1.39 | -613 | 65.9K | -0.9% | -$852.07 | |
| 2025-05-16 | 2025-05-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $1.14 | -613 | 66.5K | -0.9% | -$698.82 | |
| 2025-02-19 | 2025-02-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $5.42 | -724 | 67.1K | -1% | -$3,924 | |
| 2024-11-18 | 2024-11-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $7.92 | -613 | 67.9K | -0.9% | -$4,855 | |
| 2024-08-16 | 2024-08-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $7.02 | -613 | 68.5K | -0.9% | -$4,303 | |
| D | 2024-05-21 | 2024-05-17 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | M - OptEx | $1.04 | +10.0K | 69.1K | +17% | +$10.4K |
| 2024-05-16 | 2024-05-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $8.36 | -613 | 59.1K | -1% | -$5,125 | |
| 2024-02-16 | 2024-02-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $3.40 | -723 | 59.7K | -1% | -$2,458 | |
| 2023-11-16 | 2023-11-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | F - Tax | $5.08 | -2,450 | 60.4K | -4% | -$12.4K | |
| D | 2023-06-06 | 2023-06-05 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | M - OptEx | $1.04 | +9,225 | 62.9K | +17% | +$9,594 |
| D | 2022-11-16 | 2022-11-14 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | A - Grant | $0.00 | +33.4K | 53.7K | +165% | $0 |
Purchase Sale Sale after option exercise All abbreviations